Induced pluripotent stem cells as a new strategy for cardiac regeneration and disease modeling

Journal of Molecular and Cellular Cardiology

Volumn 62, Issue , 2013, Pages 43-50

  Iglesias García, Olalla ^a   Pelacho, Beatriz ^a   Prósper, Felipe ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cardiac differentiation; Cardiac regeneration; Cell reprogramming; Induced pluripotent stem (iPS) cells; Stem cell therapy

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHIR 99021; CYCLOSPORIN A; CYTOKINE; DANTROLENE; DORSOMORPHIN; GAMMA SECRETASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; IWR 1; IWR 2; IWR 4; NIFEDIPINE; PINACIDIL; PROTEIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BRUGADA SYNDROME; CARDIAC REGENERATION; CARDIOMYOPATHY; CELL DIFFERENTIATION; CELL TRANSPLANTATION; EPIGENETICS; FAMILIAL DILATED CARDIOMYOPATHY; GENETIC DISORDER; HEART DISEASE; HEART MUSCLE CELL; HEART VENTRICLE TACHYCARDIA; HUMAN; IN VIVO STUDY; LEOPARD SYNDROME; LONG QT SYNDROME; NONHUMAN; NUCLEAR REPROGRAMMING; PERSONALIZED MEDICINE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; TACHYCARDIA; TISSUE REGENERATION;

Γ-SECRETASE INHIBITOR; BMPS; BONE MORPHOGENETIC PROTEINS; CARDIAC DIFFERENTIATION; CARDIAC PROGENITOR CELLS; CARDIAC REGENERATION; CARDIOMYOCYTES; CATECHOLAMINE POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL REPROGRAMMING; CMS; CPCS; CPVT; DIMETHYLSULFOXIDE; DMSO; ECS; EMBRYONIC STEM CELLS; END-2; ENDODERM-LIKE CELL LINE; ENDOTHELIAL CELLS; ESCS; FETAL LIVER KINASE-1; FGF; FIBROBLAST GROWTH FACTOR; FLK-1; G-CSF; GLYCOGEN SYNTHASE KINASE-3; GRANULOCYTE COLONY-STIMULATING FACTOR; GSI; GSK3; HESCS; HIPS; HUMAN EMBRYONIC STEM CELLS; HUMAN INDUCED PLURIPOTENT STEM; INDUCED PLURIPOTENT STEM; INDUCED PLURIPOTENT STEM (IPS) CELLS; IPS; ISL1; ISLET-1; JAK-STAT; JANUS KINASE-SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; LEUKEMIA INHIBITORY FACTOR; LIF; MI; MYOCARDIAL INFARCTION; OCT3/4, KLF-4, SOX-2, AND C-MYC; OSKM; SCF; SMCS; SMOOTH MUSCLE CELLS; STEM CELL FACTOR; STEM CELL THERAPY; TGFΒ; TRANSFORMING GROWTH FACTOR-Β; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; HEART; HUMANS; INDUCED PLURIPOTENT STEM CELLS; REGENERATION;

IPS;

EID: 84878730741     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.04.022     Document Type: Review

References (86)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart Disease and Stroke Statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:6-245.
2. Passier R., van Laake L.W., Mummery C.L. Stem-cell-based therapy and lessons from the heart. Nature 2008, 453:322-329.
3. Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114:763-776.
4. Hsieh P.C., Segers V.F., Davis M.E., MacGillivray C., Gannon J., Molkentin J.D., et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 2007, 13:970-974.
5. Winter E.M., van Oorschot A.A., Hogers B., van der Graaf L.M., Doevendans P.A., Poelmann R.E., et al. A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circ Heart Fail 2009, 2:643-653.
6. Tang X.L., Rokosh G., Sanganalmath S.K., Yuan F., Sato H., Mu J., et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 2010, 121:293-305.
7. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
8. Senyo S.E., Steinhauser M.L., Pizzimenti C.L., Yang V.K., Cai L., Wang M., et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013, 493:433-436.
9. Laflamme M.A., Chen K.Y., Naumova A.V., Muskheli V., Fugate J.A., Dupras S.K., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007, 25:1015-1024.
10. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
11. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
12. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
13. Stadtfeld M., Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010, 24:2239-2263.
14. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481:295-305.
15. Feng B., Ng J.H., Heng J.C., Ng H.H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009, 4:301-312.
16. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
17. Niwa H., Burdon T., Chambers I., Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 1998, 12:2048-2060.
18. Williams R.L., Hilton D.J., Pease S., Willson T.A., Stewart C.L., Gearing D.P., et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 1988, 336:684-687.
19. Ying Q.L., Nichols J., Chambers I., Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003, 115:281-292.
20. Smith A.G. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol 2001, 17:435-462.
21. Xiao L., Yuan X., Sharkis S.J. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells 2006, 24:1476-1486.
22. Chin M.H., Mason M.J., Xie W., Volinia S., Singer M., Peterson C., et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009, 5:111-123.
23. Wilson K.D., Venkatasubrahmanyam S., Jia F., Sun N., Butte A.J., Wu J.C. MicroRNA profiling of human-induced pluripotent stem cells. Stem Cells Dev 2009, 18:749-758.
24. Marchetto M.C., Yeo G.W., Kainohana O., Marsala M., Gage F.H., Muotri A.R. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One 2009, 4:e7076.
25. Ghosh Z., Wilson K.D., Wu Y., Hu S., Quertermous T., Wu J.C. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One 2010, 5:e8975.
26. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
27. Araki R., Uda M., Hoki Y., Sunayama M., Nakamura M., Ando S., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
28. Nelson T.J., Martinez-Fernandez A., Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol 2010, 7:700-710.
29. Kobayashi T., Yamaguchi T., Hamanaka S., Kato-Itoh M., Yamazaki Y., Ibata M., et al. Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 2010, 142:787-799.
30. Nelson T.J., Martinez-Fernandez A., Yamada S., Perez-Terzic C., Ikeda Y., Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 2009, 120:408-416.
31. Polo J.M., Liu S., Figueroa M.E., Kulalert W., Eminli S., Tan K.Y., et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010, 28:848-855.
32. Bar-Nur O., Russ H.A., Efrat S., Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 2011, 9:17-23.
33. Mauritz C., Schwanke K., Reppel M., Neef S., Katsirntaki K., Maier L.S., et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008, 118:507-517.
34. Carpenter L., Carr C., Yang C.T., Stuckey D.J., Clarke K., Watt S.M. Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat. Stem Cells Dev 2011, 21:977-986.
35. Narazaki G., Uosaki H., Teranishi M., Okita K., Kim B., Matsuoka S., et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008, 118:498-506.
36. Schenke-Layland K., Rhodes K.E., Angelis E., Butylkova Y., Heydarkhan-Hagvall S., Gekas C., et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 2008, 26:1537-1546.
37. Taura D., Sone M., Homma K., Oyamada N., Takahashi K., Tamura N., et al. Induction and isolation of vascular cells from human induced pluripotent stem cells-brief report. Arterioscler Thromb Vasc Biol 2009, 29:1100-1103.
38. Mauritz C., Martens A., Rojas S.V., Schnick T., Rathert C., Schecker N., et al. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J 2011, 32:2634-2641.
39. Moretti A., Bellin M., Jung C.B., Thies T.M., Takashima Y., Bernshausen A., et al. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J 2009, 24:700-711.
40. Xi J., Khalil M., Shishechian N., Hannes T., Pfannkuche K., Liang H., et al. Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J 2010, 24:2739-2751.
41. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740.
42. Burridge P.W., Anderson D., Priddle H., Barbadillo Munoz M.D., Chamberlain S., Allegrucci C., et al. Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells 2007, 25:929-938.
43. Burridge P.W., Thompson S., Millrod M.A., Weinberg S., Yuan X., Peters A., et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011, 6:e18293.
44. Elliott D.A., Braam S.R., Koutsis K., Ng E.S., Jenny R., Lagerqvist E.L., et al. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat Methods 2011, 8:1037-1040.
45. Zhang J., Klos M., Wilson G.F., Herman A.M., Lian X., Raval K.K., et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res 2012, 111:1125-1136.
46. Blin G., Nury D., Stefanovic S., Neri T., Guillevic O., Brinon B., et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010, 120:1125-1139.
47. Chan S.S., Li H.J., Hsueh Y.C., Lee D.S., Chen J.H., Hwang S.M., et al. Fibroblast growth factor-10 promotes cardiomyocyte differentiation from embryonic and induced pluripotent stem cells. PLoS One 2011, 5:e14414.
48. Yuasa S., Itabashi Y., Koshimizu U., Tanaka T., Sugimura K., Kinoshita M., et al. Transient inhibition of BMP signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic stem cells. Nat Biotechnol 2005, 23:607-611.
49. Lian X., Hsiao C., Wilson G., Zhu K., Hazeltine L.B., Azarin S.M., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 2012, 109:E1848-E1857.
50. Willems E., Spiering S., Davidovics H., Lanier M., Xia Z., Dawson M., et al. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ Res 2011, 109:360-364.
51. Ren Y., Lee M.Y., Schliffke S., Paavola J., Amos P.J., Ge X., et al. Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J Mol Cell Cardiol 2011, 51:280-287.
52. Naito A.T., Shiojima I., Akazawa H., Hidaka K., Morisaki T., Kikuchi A., et al. Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci U S A 2006, 103:19812-19817.
53. Ueno S., Weidinger G., Osugi T., Kohn A.D., Golob J.L., Pabon L., et al. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci U S A 2007, 104:9685-9690.
54. Kwon C., Arnold J., Hsiao E.C., Taketo M.M., Conklin B.R., Srivastava D. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. Proc Natl Acad Sci U S A 2007, 104:10894-10899.
55. Kattman S.J., Witty A.D., Gagliardi M., Dubois N.C., Niapour M., Hotta A., et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 2011, 8:228-240.
56. Kitamura R., Takahashi T., Nakajima N., Isodono K., Asada S., Ueno H., et al. Stage-specific role of endogenous Smad2 activation in cardiomyogenesis of embryonic stem cells. Circ Res 2007, 101:78-87.
57. Willems E., Cabral-Teixeira J., Schade D., Cai W., Reeves P., Bushway P.J., et al. Small molecule-mediated TGF-beta type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell 2012, 11:242-252.
58. Jang J., Ku S.Y., Kim J.E., Choi K., Kim Y.Y., Kim H.S., et al. Notch inhibition promotes human embryonic stem cell-derived cardiac mesoderm differentiation. Stem Cells 2008, 26:2782-2790.
59. Cao N., Liu Z., Chen Z., Wang J., Chen T., Zhao X., et al. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res 2011, 22:219-236.
60. Xu C., Police S., Rao N., Carpenter M.K. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 2002, 91:501-508.
61. Shimoji K., Yuasa S., Onizuka T., Hattori F., Tanaka T., Hara M., et al. G-CSF promotes the proliferation of developing cardiomyocytes in vivo and in derivation from ESCs and iPSCs. Cell Stem Cell 2010, 6:227-237.
62. Fujiwara M., Yan P., Otsuji T.G., Narazaki G., Uosaki H., Fukushima H., et al. Induction enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One 2011, 6:e16734.
63. Efe J.A., Hilcove S., Kim J., Zhou H., Ouyang K., Wang G., et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011, 13:215-222.
64. Margariti A., Winkler B., Karamariti E., Zampetaki A., Tsai T.N., Baban D., et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A 2012, 109:13793-13798.
65. Takeuchi J.K., Bruneau B.G. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature 2009, 459:708-711.
66. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
67. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598.
68. Srivastava D., Ieda M., Fu J., Qian L. Cardiac repair with thymosin beta4 and cardiac reprogramming factors. Ann N Y Acad Sci 2012, 1270:66-72.
69. Song K., Nam Y.J., Luo X., Qi X., Tan W., Huang G.N., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485:599-604.
70. Chen J.X., Krane M., Deutsch M.A., Wang L., Rav-Acha M., Gregoire S., et al. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res 2012, 111:50-55.
71. Jayawardena T.M., Egemnazarov B., Finch E.A., Zhang L., Payne J.A., Pandya K., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012, 110:1465-1473.
72. Rane A.A., Christman K.L. Biomaterials for the treatment of myocardial infarction: a 5-year update. J Am Coll Cardiol 2011, 58:2615-2629.
73. Matsuura K., Wada M., Shimizu T., Haraguchi Y., Sato F., Sugiyama K., et al. Creation of human cardiac cell sheets using pluripotent stem cells. Biochem Biophys Res Commun 2012, 425:321-327.
74. Tulloch N.L., Muskheli V., Razumova M.V., Korte F.S., Regnier M., Hauch K.D., et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 2011, 109:47-59.
75. Dai B., Huang W., Xu M., Millard R.W., Gao M.H., Hammond H.K., et al. Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function. J Am Coll Cardiol 2011, 58:2118-2127.
76. Kawamura M., Miyagawa S., Miki K., Saito A., Fukushima S., Higuchi T., et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012, 126:S29-S37.
77. Shiba Y., Fernandes S., Zhu W.Z., Filice D., Muskheli V., Kim J., et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 2012, 489:322-325.
78. Bellin M., Marchetto M.C., Gage F.H., Mummery C.L. Induced pluripotent stem cells: the new patient?. Nat Rev Mol Cell Biol 2012, 13:713-726.
79. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812.
80. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010, 363:1397-1409.
81. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
82. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234.
83. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkela E., et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2011, 5:220-230.
84. Sun N., Yazawa M., Liu J., Han L., Sanchez-Freire V., Abilez O.J., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012, 4:130ra47.
85. Davis R.P., Casini S., van den Berg C.W., Hoekstra M., Remme C.A., Dambrot C., et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012, 125:3079-3091.
86. Jung C.B., Moretti A., Mederos y Schnitzler M., Iop L., Storch U., Bellin M., et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2011, 4:180-191.